

DESCRIPTION

Source	Human embryonic kidney cell, HEK293-derived		
	Cynomolgus Monkey CTLA-4 (Ala37-Asp161) Accession # XP_005574071	IEGRMD	Human IgG ₁ (Pro100-Lys330)
	N-terminus		C-terminus

N-terminal Sequence Analysis Ala37

Structure / Form Disulfide-linked homodimer

Predicted Molecular Mass 40 kDa

SPECIFICATIONS

SDS-PAGE 46-57 kDa, reducing conditions

Activity Measured by its binding ability in a functional ELISA.
When Recombinant Cynomolgus Monkey CTLA-4 Fc Chimera is coated at 0.5 µg/mL, 100 µL/well, Recombinant Human B7-1/CD80 Fc Chimera (Catalog # 140-B1) binds with an ED₅₀ of 5-30 ng/mL.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Reconstitute at 1 mg/mL in PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

CTLA-4 (cytotoxic T-lymphocyte-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Cyno CTLA-4 has a 98% homology to human CTLA-4. Human or mouse CTLA-4 cDNA encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence. It is found as a covalent homodimer of 41-43 kDa (2). Within the ECD, human CTLA-4 shares 98%, 68%, 71% and 83-86% aa sequence identity with cynomolgus, mouse, rat and porcine/bovine/rabbit/feline/canine CTLA-4, respectively. A 174 aa form that lacks TM and cytoplasmic sequences (sCTLA-4) is possibly secreted (3-5). In mouse, an isoform lacking the Ig-like domain has ligand-independent inhibitory activity and is termed liCTLA-4 (6). CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 7, 8). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1-2 days after T cell activation (2, 7, 8). It forms a linear lattice with B7-1 on APC, inducing negative regulatory signals and ending T cell activation (9). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (10). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (11-13).

References:

1. Harper, K. et al. (1991) *J. Immunol.* **147**:1037.
2. Teft, W.A. et al. (2006) *Annu. Rev. Immunol.* **24**:65.
3. Magistrelli, G. et al. (1999) *Eur. J. Immunol.* **29**:3596.
4. Tector, M. et al. (2009) *BMC Immunol.* **10**:51.
5. Oaks, M.K. and K.M. Hallett (2000) *J. Immunol.* **164**:5015.
6. Vijayakrishnan, L. et al. (2004) *Immunity* **20**:563.
7. Pentcheva-Hoang, T. et al. (2004) *Immunity* **21**:401.
8. Jansson, A. et al. (2005) *J. Immunol* **175**:1575.
9. Darlington, P.J. et al. (2005) *J. Immunol.* **175**:996.
10. Platt, A.M. et al. (2010) *J. Immunol.* **185**:1558.
11. Wing, K. et al. (2008) *Science.* **322**: 271.
12. Friedline, R.H. et al. (2009) *J. Exp. Med.* **206**:421.
13. Jain, N. et al. (2010) *Proc. Natl. Acad. Sci. USA.* **107**:1524.